Seamus Mulligan - 09 May 2025 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role
Director
Signature
By: /s/Adam Guttmann, as attorney in fact For: Seamus Mulligan
Issuer symbol
JAZZ
Transactions as of
09 May 2025
Net transactions value
+$9,993,082
Form type
4
Filing time
13 May 2025, 18:51:34 UTC
Previous filing
06 Aug 2024
Next filing
11 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mulligan Seamus Director 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, IRELAND By: /s/Adam Guttmann, as attorney in fact For: Seamus Mulligan 13 May 2025 0001536639

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAZZ Ordinary Shares Purchase $7,915,472 +80,684 $98.10 80,684 09 May 2025 By Nerano Pharma Lim F1, F2
transaction JAZZ Ordinary Shares Purchase $1,900,678 +19,216 +24% $98.91 99,900 09 May 2025 By Nerano Pharma Lim F2, F3
transaction JAZZ Ordinary Shares Purchase $9,971 +100 +0.1% $99.71 100,000 09 May 2025 By Nerano Pharma Lim F2
transaction JAZZ Ordinary Shares Purchase $166,962 +1,621 +1.6% $103.00 101,621 12 May 2025 By Nerano Pharma Lim F2, F4
holding JAZZ Ordinary Shares 1,176,106 09 May 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $97.56 to $98.5542. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.
F2 Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family.
F3 Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $98.56 to $99.47. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.
F4 Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $102.97 to $103.00. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.